Loading
A phase 1/2 trial of Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin in endometrial cancer, run by Huabo Biopharm Co., Ltd., now recruiting.
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06758557 by Huabo Biopharm Co., Ltd., with 282 participants planned, started 2024-01-31 and due to reach its primary completion in 2025-10-31. Interventions recorded: HB0025, Pemetrexed, Paclitaxel, Carboplatin. Conditions listed: Advanced NSCLC, Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Huabo Biopharm, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Huabo Biopharm, Pemetrexed, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/